Core Viewpoint - *ST Huicheng has signed a restructuring investment agreement with Zhi'en Biotechnology, which is a national high-tech enterprise engaged in pharmaceutical research, production, sales, and health services [1] Group 1: Company Overview - Zhi'en Biotechnology has established a drug lifecycle management service system centered on MAH, providing comprehensive services including research, manufacturing, sales, and post-market studies [1] - The company has received several national qualifications, including National Enterprise Technology Center and National Specialized and Innovative "Little Giant" Enterprise [1] Group 2: Restructuring Process - The signing of the restructuring investment agreement is a necessary step for the company's pre-restructuring and restructuring procedures, facilitating the smooth progress of these processes [1] - The company and supporting institutions will draft a restructuring plan based on the agreement, considering actual conditions and communications with investors, creditors, and contributors [1] - The implementation of the restructuring agreement will ultimately depend on the court's approval of the restructuring plan after the company enters the restructuring process [1]